Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hudi Changrong Capsule versus mesalazine in mild active ulcerative colitis
ChiCTR1900023158Phase 4Recruiting
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Hudi Changrong and Salcrozine in autoimmune colitis (2 arms), sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Clinical effective rate and Clinical remission rate. Started May 2019; status: recruiting.
02
Drugs
Hudi ChangrongSalcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR1900023158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023158.